The Use of FOLFOX4 Regimen in Stage IV Cervical Cancer: A Pilot Study

Abstract

Objective: To evaluate the efficacy and safety of FOLFOX4 (oxaliplatin/5FU/Leucovorin) for the treatment of metastatic cervical cancer. Methods: All patients were designed to receive the FOLFOX4 regimen (Oxaliplatin (Eloxatin ^&reg ) 85 mg/m 2 D1, 5-Fluorouracil 400 mg/m 2 IV push D1-2, 5-Fluorouracil 600 mg/m 2 IV drip in 22 hours D1-2 and Folinic acid 200 mg/m 2 IV push in D1-2). The treatment responsiveness and toxicities were evaluated. Results: Thirty patients from January 2010-December 2012 were enrolled into the study. The mean age was 51 years old. Nine patients (31%) achieved objective response. At the mean follow-up time of 13 months, the one-year progression-free and overall survival rates were 20.7% and 65.5%, respectively. The most common grade 3 adverse event reported in this study was anemia (36.7%), thrombocytopenia (16.7%) and fatigue (16.7%). Conclusions: FOLFOX4 regimen in metastatic cervical cancer is feasible.